N/A N=146 Swallowing Function Before and After Surgery for Thyroid Goiter
Hypothyroidism
Primary: Swallowing Quality of Life — 84.6; 92.3; 81.2; 87.1 units on a scale — p=0.0007
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=299 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
Breast Cancer · Musculoskeletal Complications · Pain
Primary: Average Joint Pain According to BPI-SF — 2.9; 3.5 units on a scale — p=0.0002
N/A N=43 Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion
Stenosis · Spondylosis · Degenerative Changes
Primary: Number of Radiographic Assessments That Indicate Posterolateral Fusion at 12 Months Post Surgery — 43; 74 radiographic assessments
Phase 2 N=181 Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
Phase 4 N=223 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
Overactive Bladder
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 23; 21; 42; 69 Participants
N/A N=177 New Ways to Help Patients Improve Their Diabetes Control
Diabetes Mellitus
Primary: Change in Percent of Glycosylated Hemoglobin 6 Months Following Enrollment — -0.74; -0.55; -0.89 Percent of glycosylated hemoglobin
N/A N=446 The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
Chronic Heart Failure
Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110
Phase 3 N=102 Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
Chronic Scalp Psoriasis
Primary: Psoriasis Scalp Severity Index 90 (PSSI 90) — 52.9; 2.0 Percent of Participants — p=<0.001
N/A N=20 Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study
Type 1 Diabetes Mellitus
Primary: Percentage of Nights With CGM (Continuous Glucose Monitor) Sensor Values < 60 mg/dL — 24; 12; 25; 11 percentage of nights
Phase 3 N=606 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants
Phase 3 N=608 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT) — 83.4; 82.1 Adjusted percentage of participants
Phase 3 N=781 Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Colorectal Cancer Metastatic
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 769; 609; 272; 159 Participants
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Phase 2 N=77 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Leishmaniasis
Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants
Phase 3 N=204 Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure — 34.9; 68.6; 33.3; 87.9…